Skip to main content
SpringerLink
Log in

Practical aspects in the use of cyclosporin in paediatric nephrology

  • Practical Pediatric Nephrology
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Many factors must be considered for the effective and safe use of cyclosporin A (CsA) in paediatric nephrology. Detailed knowledge of the variable bioavailability, tissue distribution, and metabolism, as well as causes which lead to their alteration are necessary. Factors which affect the activity of the mixed function oxidase system cytochrome P-450 must be considered, i. e. liver dysfunction and many drugs. Precise knowledge of the CsA determination method and the spectrum of metabolites is essential. In children with renal transplants, a body surface area-related dose will better meet the dose requirements than a body weight related-dose. For drug level monitoring whole blood rather than plasma should be used, and the parent drug level should be the main determinant; elevated metabolite levels may be important in suspected nephrotoxicity or liver dysfunction. Pharmacokinetic profiles are necessary to discover absorption problems or increased CsA clearance rates which necessitate shorter dosing intervals. In children with steroid-dependent minimal change nephrotic syndrome, remission without steroids is maintained as long as CsA is given. The appropriate starting dosage is 150 mg/m2 per day; trough level monitoring is mandatory to prevent nephrotoxicity and to confirm adequate immunosuppressive drug levels which should be 80–160 ng/ml (parent drug level). Although the benefit of CsA has been reported in some cases of lupus erythematosus, its use should be restricted to severe cases only until its efficacy and safety has been confirmed in controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Borel JF, Feurer C, Gubler HU, Stähelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468–475

    Google Scholar 

  2. Borel FJ (1989) The cyclosporins. Transplant Proc 21: 810–815

    Google Scholar 

  3. Petcher TJ, Weber HP, Rügger A (1976) Crystal and molecular structure of an iodo-derivate of the cyclic undecapeptide cyclosporin A. Helv Chim Acta 59: 1480–1488

    Google Scholar 

  4. Sandoz, Basel (1990) Postmarketing surveillance

  5. Mason J (1990) The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 4: 554–574

    Google Scholar 

  6. Grevel J, Kahan B (1989) Pharmacokinetics of cyclosporin A. In: Thomson AW (ed) Cyclosporin, mode of action and clinical applications. Dordrecht, pp 252–266

  7. Grevel J (1986) Absorption of cyclosporin A after oral dosing. Transplant Proc 18 [Suppl 5]: 9–15

    Google Scholar 

  8. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR (1985) The effect of food on cyclosporine absorption. Transplantation 40: 174–176

    Google Scholar 

  9. Canafax DM, Cipolle RJ, Hrushesky WJM, Rabatin JT, Min DI, Graves NM, Sutherland DER, Bowers LD (1988) The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc 20 [Suppl 2]: 471–477

    Google Scholar 

  10. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL (1990) Small bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 322: 733–738

    Google Scholar 

  11. Nashan B, Bleck J, Wonigeit K (1988) Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules. Transplant Proc 20 [Suppl 2]: 637–639

    Google Scholar 

  12. Wagner O, Schreier E, Heitz F, Maurer G (1987) Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos 15: 377–383

    Google Scholar 

  13. Beveridge T (1982) Pharmacokinetics and metabolism of cyclosporin A. In: White DJG (ed) Cyclosporin A: Proceedings of an International Conference on Cyclosporin A. Elsevier, Amsterdam, pp 35–44

    Google Scholar 

  14. Follath F, Wnk M, Vozeh S (1983) Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34: 638–643

    Google Scholar 

  15. Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15: 446–453

    Google Scholar 

  16. Maurer G (1985) Metabolism of cyclosporine. Transplant Proc 17 [Suppl 1]: 19–26

    Google Scholar 

  17. Maurer G, Lemaire M (1986) Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 18 [Suppl 5]: 25–34

    Google Scholar 

  18. Lemaire M, Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 34: 715–718

    Google Scholar 

  19. Atkinson K, Britton K, Biggs J (1984) Distribution and concentration of cyclosporin in human blood. J Clin Pathol 37: 1167–1171

    Google Scholar 

  20. Niederberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O (1983) Distribution and binding of cyclosporin in blood and tissue. Transplant Proc 15: 2419–2421

    Google Scholar 

  21. Gurecki J, Warty V, Sanghvi A (1985) The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc 17: 1997–2002

    Google Scholar 

  22. Bellitsky P, Ghose T, Givner M, Rowden G, Pope B (1985) Tissue distribution of cyclosporin A in the mouse: a clue to toxicity? Clin Nephrol 25 [Suppl 1]: 27–29

    Google Scholar 

  23. Backman L, Brandt I, Dallner G, Ringden O (1988) Tissue distribution of (3H)cyclosporine in mice. Transplant Proc 20 [Suppl 2]: 684–691

    Google Scholar 

  24. Burckart GJ, Venkataramanan R, Starzl TE, Ptachcinski RJ, Gartner CJ, Rosenthal T (1984) Cyclosporine clearance in children following organ transplantation. J Clin Pharmacol 24: 412–416

    Google Scholar 

  25. Venkataramanan R, Burckart GJ, Ptachcinski RJ (1985) Pharmacokinetics and monitoring of cyclosporin following orthotopic liver transplantation. Semin Liver Dis 5: 357–368

    Google Scholar 

  26. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ (1986) Age-dependent cyclosporine pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 40: 438–443

    Google Scholar 

  27. Rosano TG, Freed BM, Cerilli J, Lempert N (1986) Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients. Transplantation 42: 262–266

    Google Scholar 

  28. Maurer G, Loosli HR, Schreier E, Keller B (1984) Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos 12: 120–126

    Google Scholar 

  29. Quesniaux VFJ (1989) Pharmacology of cyclosporine (Sandimmune). III. Immunochemistry and monotoring. Pharmacol Rev 41: 249–258

    Google Scholar 

  30. Cheung F, Wong PY, Loo J, Cole EH, Levy GA (1988) Identification of cyclosporine metabolites in human bile, blood, and urine by high-performance liquid chromatography/radioimmunoassay/fast atomic bombardment mass spectroscopy. Transplant Proc 20 [Suppl 2]: 602–608

    Google Scholar 

  31. Freed BM, Rosano TG, Lempert N (1987) In vitro immunosuppressive properties of cyclosporine metabolites. Transplantation 43: 123–127

    Google Scholar 

  32. Schlitt HJ, Christians U, Bleck J, Kohlhaw K, Ringe B, Bunzendahl H, Sewing KF, Wonigeit K, Pichlmayr R (1991) Contribution of cyclosporin metabolites to immunosuppression in liver-transplanted patients with severe graft dysfunction. Transplant Int 4: in press

  33. Rosano TG, Freed BM, Fell MA, Lempert N (1986) Cyclosporine metabolites in human blood and renal tissue. Transplant Proc 18 [Suppl 5]: 35–40

    Google Scholar 

  34. Zeevi A, Eiras G, Burckart G, Makowka L, Venkataramenan R, Wang C, Van Thiel DH, Murase N, Starzl T, Duquesnoy R (1988) Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells. Transplant Proc 20 [Suppl 2]: 115–121

    Google Scholar 

  35. Chabannes D, Moreau JF, Soulillou JP (1987) Effect of cyclosporine, cyclosporine metabolite 17, and other cyclosporine-related compounds on T lymphocyte clones derived from rejected human kidney grafts. Transplantation 44: 813–817

    Google Scholar 

  36. Freed BM, Rosano TG, Quick C, Lempert N (1987) Effects of cyclosporine metabolites M17 and M18 on proliferation and IL-2 production in the mixed lymphocyte culture. Transplant Proc 19: 1223–1226

    Google Scholar 

  37. Ryffel B, Foxwell BMJ, Mihatsch MJ, Donatsch P, Maurer G (1988) Biologic significance of cyclosporine metabolites. Transplant Proc 20 [Suppl 2]: 575–584

    Google Scholar 

  38. Lensmeyer G, Wiebe D, Calson I (1988) Deposition of nine metabolites of cyclosporine in human tissues, bile urine and whole blood. Transplant Proc 20 [Suppl 2]: 614–622

    Google Scholar 

  39. Leunissen K, Bosman F, Beuman G, Hoof J van (1988) The nephrotoxic effects of cyclosporine metabolites. Transplant Proc 20 [Suppl 3]: 738–739

    Google Scholar 

  40. Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N (1988) Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplant Proc 20 [Suppl 2]: 330–338

    Google Scholar 

  41. Roberts NB, Lane C, Scott MH, Sells RA (1988) The measurement of cyclosporin A and metabolite M17 in whole blood by high performance liquid chromatography. Transplant Proc 20 [Suppl 2]: 625–632

    Google Scholar 

  42. Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R (1990) Cyclosporin monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 22: 1305–1311

    Google Scholar 

  43. Cockburn I, Krupp P (1989) Sandimmun—an appraisal of drug interactions. In: Andreucci VE, Del Canton A (eds), Current therapy in nephrology. Kluwer, Boston pp 503–518

    Google Scholar 

  44. Scott JPP, Higenbottam TW (1988) Adverse reactions and interactions of cyclosporin. Med Toxicol 3: 107–127

    Google Scholar 

  45. Burke MD, McIntyre F, Cameron D, Whiting PH (1989) Cyclosporin A metabolism and drug interactions. In: Thomson AW (ed) Cyclosporin, mode of action nd clinical applications. Kluwer, Dordrecht, pp 267–302

    Google Scholar 

  46. Ptachcinski RJ, Venkatarmanan R, Burckart GJ (1986) Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11: 107–132

    Google Scholar 

  47. Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR (1984) Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 38: 304–306

    Google Scholar 

  48. Rowland M, Gupta SK (1987) Cyclosporin-phenytoin interaction: reevaluation using metabolite data. Br J Clin Pharmacol 24: 329–334

    Google Scholar 

  49. Schwass DE, Sasaki AW, Houghton DC, Benner KE, Bennett WM (1985) Effect of phenobarbital and cimetidine on experimental cyclosporine nephrotoxicity: preliminary observations. Clin Nephrol 25 [Suppl 1]: 117–120

    Google Scholar 

  50. Daniels NJ, Dover JS, Schachter RK (1984) Interaction between cyclosporin and rifampicin. Lancet II: 639

    Google Scholar 

  51. Allen RD, Hunnisett AG, Morris PJ (1985) Cyclosporin and rifampicin in renal transplantation. Lancet I: 980

    Google Scholar 

  52. Langhoff E, Madsen S (1983) Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment. Lancet II: 1031

    Google Scholar 

  53. Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR (1984) Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 38: 304–305

    Google Scholar 

  54. Freeman DJ, Laupacis A, Keown PA, Stiller C, Carruthers SG (1984) Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 18: 887–893

    Google Scholar 

  55. Wood AJ, Maurer G, Niederberger W, Beveridge T (1983) Cyclosporine: pharmacokinetics, metabolism and drug interactions. Transplant Proc 15 [Suppl 1]: 2409–2412

    Google Scholar 

  56. Carstensen H, Jacobsen N (1986) Interaction between cyclosporin A and phenobarbitone. Br J Clin Pharmacol 21: 550–551

    Google Scholar 

  57. Lele P, Peterson P, Yang S, Jarrell B, Burke JF (1985) Cyclosporine and tegretal—another drug interaction. Kidney Int 27: 344

    Google Scholar 

  58. Durrant S, Chipping PM, Palmer S, Gordon-Smith EC (1982) Cyclosporin A methylprednisolone and convulsions. Lancet II: 829–830

    Google Scholar 

  59. Boogaerts MA, Zachee P, Verwilghen RL (1982) Cyclosporine, methyl-prednisolone and convulsions. Lancet II: 1217

    Google Scholar 

  60. Ptachcinski RJ, Carpenter BJ, Burckart GJ, Venkataramanan R, Rosenthal JT (1985) Effect of erythromycin on cyclosporine levels. N Engl J Med 313: 1416–1417

    Google Scholar 

  61. Martell R, Heinrichs D, Stiller CR, Jenner M, Keown PA, Dupre J (1986) The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 104: 660–661

    Google Scholar 

  62. Hourmant M, Le Bigot JF, Vernillet L, Sagniez G, Remi JP, Soulillou JP (1985) Coadministration of erythromycin results in an increase of blood cyclosporine to toxic levels. Transplant Proc 17: 2723–2727

    Google Scholar 

  63. D'Soza MJ, Pollock SH, Solomon HM (1988) Cyclosporinecimetidine interaction. Drug Metab Dispos 16: 57–59

    Google Scholar 

  64. Babany G, Morris RE, Babany I, Shepherd S, Kates RE (1988) Effects of the administration of cimetidine or phenobarbital on the immunosuppression of cyclosporine in mice in vivo. Transplant Proc 20

  65. Freeman DJ, Laupacis A, Keown P, Stiller C, Carruthers G (1984) The effect of agents that alter drug metabolising enzyme activity on the pharmacokinetics of cyclosporine. Ann R Coll Phys Surg Can 17: 301

    Google Scholar 

  66. White DJG, Blatchford NR, Cauwenbergh G (1984) Cyclosporine and ketoconazole. Transplantation 37: 214–215

    Google Scholar 

  67. Gumbleton M, Brown JE, Hawksworth G, Whiting PH (1985) The possible relationship between heptic drug metabolism and ketoconazole enhancement of cyclosporine A-nephrotoxicity. Transplantation 46: 454–456

    Google Scholar 

  68. Dieperink H, Moller J (1982) Ketoconazole and cyclosporin. Lancet II: 1217

    Google Scholar 

  69. Ferguson RM, Sutherland DFR, Simmons RL, Najarian JS (1982) Ketoconazole, cyclosporine metabolism and renal transplantation. Lancet II: 882–883

    Google Scholar 

  70. Grino JM, Sabate I, Castelao AM, Alsina J (1986) Influence of diltiazem on cyclosporin clearance. Lancet I: 1387

    Google Scholar 

  71. Pochet JM, Pirson Y (1986) Cyclosporin-diltiazem interaction. Lancet I: 979

    Google Scholar 

  72. Neumayer HH, Wagner K (1986) Diltiazem and economic use of cyclosporin. Lancet II: 523

    Google Scholar 

  73. Ross WB, Roberts D, Griffin PJA, Salaman JR (1986) Cyclosporin interaction with danazol and norethisterone. Lancet I: 330

    Google Scholar 

  74. Schroder O, Schmitz N, Kayser W, Euler HH, Loffler H (1986) Erhöhte Ciclosporin-A-Spiegel bei gleichzeitiger Therapie mit danazol. D Med Wochenschr 111: 602–603

    Google Scholar 

  75. Whiting PH, Cunningham C, Thomson AW, Simpson JG (1984) Enhancement of high dose cyclosporin A toxicity by frusemide. Biochem Pharmacol 33: 1075–1079

    Google Scholar 

  76. Fabre I, Fabre G, Maurel G, Bertault-Peres P, Cano JP (1988) Metabolism of cyclosporin A. III. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions. Drug Metab Dispos 16: 296–301

    Google Scholar 

  77. Wallwork J, McGregor CGA, Wells FC, Cory-Pearce R, English TAH (1983) Cyclosporin and intravenous sulphadimidine and trimethoprim therapy. Lancet I: 366–367

    Google Scholar 

  78. Jones DK, Hakim M, Wallwork J, Higenbottam TW, White DJG (1986) Serious interaction between cyclosporin A and sulphadimidine. BMJ 292: 728–729

    Google Scholar 

  79. Termeer A, Hoitsma AJ, Koene RAP (1986) Severe nephrotoxicity caused by the combined use of gentamycin and cyclosporin in renal allograft recipients. Transplantation 42: 220–221

    Google Scholar 

  80. Burke MD, Whiting PH (1986) The role of drug metabolism in cyclosporine A nephrotoxicity. Clin Nephrol 25 [Suppl 1]: 111–116

    Google Scholar 

  81. Tobert JA (1988) Correspondence. N Engl J Med 318: 48

    Google Scholar 

  82. Bohnhorst B, Offner G, Albers N, Beier CJ (1990) Gingivahyperplasie bei nierentransplantierten Patienten. Monatsschr Kinderheilk 138: 568

    Google Scholar 

  83. McCauley J, Fung J, Jain A, Todo S, Starzl TE (1990) The effect of FK 506 on renal function after liver transplantation. Transplant Proc 22 (suppl 1): 17–20

    Google Scholar 

  84. Argawal RP, McPherson RA, Threatte GA (1985) Assessment of cyclosporin A in whole blood and plasma of five patients with different hematocrits. Ther Drug Monit 7: 61–65

    Google Scholar 

  85. Rosano TG (1985) Effect of hematocrit on cyclosporine (cycloporin-A) in whole blood and plasma of renal-transplant patients. Clin Chem 31: 410–412

    Google Scholar 

  86. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring (1987). Clin Chem 33: 1269–1288

  87. Donatsch P, Abisch E, Homberger M, Traber R, Trapp M, Voges R (1981) A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay 2: 19–32

    Google Scholar 

  88. Holt DW, Marsden JJ, Johnston A (1986) Measurement of cyclosporin A: methodological problems. J Immunoassay [Suppl] 18: 101–110

    Google Scholar 

  89. Niederberger W, Schaub P, Johnston A (1980) High performance liquid chromatographic determination of cyclosporin A in plasma and urine. J Chromatogr 182: 454–458

    Google Scholar 

  90. Christians U, Schlitt H, Bleck JS, Schiebel HM, Kownatzki R, Maurer G, Strohmeyer SS, Schottmann R, Wonigeit K, Pichlmayr R, Sewing, K-F (1988) Measurement of cyclosporine and 18 metabolites in blood bile and urine by high performance liquid chromatography. Transplant Proc 20 [Suppl 2]: 609–613

    Google Scholar 

  91. Pesce AJ, Schroeder TJ, First MR (1990) An evaluation of cyclosporine monitoring by non-selective fluorescence polarization immunoassay. Transplant Proc 22: 1171–1174

    Google Scholar 

  92. Yatscoff RW, Copeland KR, Faraci CJ (1990) Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 36: 1969–1973

    Google Scholar 

  93. Karol R (1990) A rapid and specific whole blood cyclosporine assay for the DuPont aca discrete clinical analyzer. Du Pont, Glasgow

    Google Scholar 

  94. Beresini M, Toton-Quinn R, Barnett B, Davalian D, Berger E, Hu M, Blohm B, Alexander L, Cerelli MJ (1990) Emit cyclosporine assay for whole blood samples on the COBAS MIRA analyzer. Syva, Palo Alto

    Google Scholar 

  95. Grevel J, Welsh M, Kahan BD (1989) Cyclosporine monitoring in renal transplantation: AUC monitoring is superior to trough level monitoring. Ther Drug Monit 11: 246–248

    Google Scholar 

  96. Alexander SR, Arbus GS, Butt KMH, Conley S, Fine RN, Greifer I, Gruskin AB, Harmon WE, McEnery PT, Nevins TE, Nogueira N, Salvatierra O Jr, Tejani A (1990) The 1989 report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 4: 542–553

    Google Scholar 

  97. Hoyer PF (1989) Optimal use of cyclosporin A in children. Pediatr Nephrol 3: C83

    Google Scholar 

  98. Canafax MD, Min DI, Matas AJ, Amend WJC, Ptachinsksi RJ, Hakala TR, Grevel J, Houghton D, Kahan BD, Simmons RL, Najarian JS, Cipolle RJ (1990) Effects of initial cyclosporine dose and timing on long-term creatinine levels in cadaver renal transplantation. Clin Transplant 4: 321–328

    Google Scholar 

  99. Broyer M, Niaudet P, Gagnadoux MF, Guest G, Dechaux M, Habib R, Beurton D (1989) Results obtained with different immunosuppressive (IS) protocols after kidney transplantation in children. Pediatr Nephrol 3: C84

    Google Scholar 

  100. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323: 1723–1728

    Google Scholar 

  101. Hoyer PF, Offner G, Wonigeit K, Brodehl J, Pichlmayr R (1984) Dosage of cyclosporin A in children with renal transplants. Clin Nephrol 22: 68–71

    Google Scholar 

  102. Hoyer PF (1990) Cyclosporin-A-Therapie bei Kindern nach Nierentransplantation. Kinderarzt 21: 325–329

    Google Scholar 

  103. Hoyer PF, Offner G, Oemar BS, Brodehl J, Ringe B, Pichlmayr R (1990) Four years' experience with cyclosporin A in pediatric kidney transplantation. Acta Paediatr Scand 79: 622–629

    Google Scholar 

  104. Thiru S (1989) Pathological effects of cyclosporin A in clinical practice. In: Thomson AW (ed) Cyclosporin, mode of action and clinical applications. Dordrecht, pp 324–364

  105. Brodehl J, Hoyer PF, Oemar BS, Helmchen U, Wonigeit K (1988) Cyclosporin treatment of nephrotic syndrome in children. Transplant Proc 20 [Suppl 4]: 269–274

    Google Scholar 

  106. Brandis M, Burghard R, Leititis J, Zimmerhackl B, Hildebrandt F, Helmchen U (1988) Cyclosporin A for the treatment of nephrotic syndrome. Transplant Proc 20 [Suppl 4] 275–279

    Google Scholar 

  107. Capodicasa G, De Santo NG, Nuzzi F, Giordano G (1986) Cyclosporin A in nephrotic syndrome of childhood—a 14 months experience. Int Pediatr Nephrol 7: 69–72

    Google Scholar 

  108. Niaudet P, Tete MJ, Broyer M, Habib R (1988) Cyclosporin and childhood idiopathic nephrosis. Transplant Proc 20 [Suppl 4]: 265–268

    Google Scholar 

  109. Tejani A, Butt K, Trachtman H (1988) Cyclosporin A induced remission of relapsing nephrotic syndrome in children. Kidney Int 33: 729–734

    Google Scholar 

  110. Lagrue G, Laurent J, Belghiti D, Robeva R (1986) Cyclosporin and idiopathic nephrotic syndrome. Lancet II: 692–693

    Google Scholar 

  111. Meyrier A, Condamin MC, Simon P (1988) Treatment with cyclosporin of adult idiopathic nephrotic syndrome resistant to corticosteroids and other immuno-suppressants. Transplant Proc 20 [Suppl 4]: 259–261

    Google Scholar 

  112. Waldo FB, Kohaut EC (1987) Therapy of focal segmental glomerulosclerosis with cyclosporin. Pediatr Nephrol 1: 180–182

    Google Scholar 

  113. Brodehl J, Brandis M, Helmchen U, Hoyer PF, Burghard R, Ehrich JHH, Zimmerhackl RB, Klein W, Wonigkeit K (1988) Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis. Klin Wochenschr 66: 1126–1137

    Google Scholar 

  114. Graffenried B, Friend D, Shand N, Schiess W, Timonen P (1990) Cyclosporin (SandimmunR) in autoimmune disorders. In: Thomson AW (ed) Cyclosporin, mode of action and clinical applications. Kluwer, Dordrecht, pp 213–251

    Google Scholar 

  115. Niaudet P (1990) Steroid resistant idiopathic nephrotic syndrome and ciclosporine. Pediatr Nephrol 4: C52

    Google Scholar 

  116. Hoyer PF (1989) Cyclosporin A in MCNS: CsA study II of the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 3: C60

    Google Scholar 

  117. Mihatsch MJ, Bach JF, Coovadia HM, Forre O, Moutsopoulos HM, Drosis AA, Siamopoulos KL, Noel LH, Ramsaroop R, Hällgren R, Svenson K, Bohman SO (1988) Cyclosporin-associated nephropathy in patients with autoimmune diseases. Klin Wochenschr 66: 43–47

    Google Scholar 

  118. Feutren G, Querin S, Noel LH, Chatenoud L, Beaurain G, Rron F, Lesavre P, Bach JF (1987) Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 111: 1063–1068

    Google Scholar 

  119. Miescher PA (1986) Treatment of systemic lupus erythematosus. Springer Semin Immunopathol 9: 271–282

    Google Scholar 

  120. Miescher PA, Favre H, Mihatsch MJ, Chatelanat F, Huang YP, Zubler R (1988) The place of cyclosporine A in the treatment of connective tissue diseases. Transplant Proc 20: 224–237

    Google Scholar 

  121. Hoyer PF, Brodehl J (1988) Therapie von schwer verlaufendem systemischen Lupus erythematodes — Hoffnung durch Cyclosporin A? (abstract) Monatsschr Kinderheilkd 136: 516

    Google Scholar 

  122. Isenberg DA, Snaith ML, Morrow WJW, Al-Khader AA, Cohen SL, Fisher C, Mowbray J (1981) Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol 3: 163–165

    Google Scholar 

  123. Ter Borg EJ, Tegzess AM, Kallenberg CGM (1988) Unexpected severe reversible cyclosporine A induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Clin Nephrol 29: 93–95

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Nephrology and Metabolic Diseases, Children's Hospital, Medical School Hannover, Konstanty Gutschowstrasse 8, W-3000, Hannover, Federal Republic of Germany

    Peter F. Hoyer, Johannes Brodehl, Jochen H. H. Ehrich & Gisela Offner

Authors
  1. Peter F. Hoyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Brodehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jochen H. H. Ehrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gisela Offner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoyer, P.F., Brodehl, J., Ehrich, J.H.H. et al. Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol 5, 630–638 (1991). https://doi.org/10.1007/BF00856658

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00856658

Key words

Search

Navigation